Head-To-Head Contrast: NKGen Biotech (NYSE:NKGN) versus Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL) and NKGen Biotech (NYSE:NKGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Insider & Institutional Ownership

76.2% of NKGen Biotech shares are held by institutional investors. 1.8% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Collegium Pharmaceutical and NKGen Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
NKGen Biotech	N/A	N/A	-479.36%

Valuation & Earnings

This table compares Collegium Pharmaceutical and NKGen Biotech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$808.21 million	1.13	$62.87 million	$1.24	22.64
NKGen Biotech	N/A	N/A	-$82.94 million	($1.68)	-0.00

Collegium Pharmaceutical has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Collegium Pharmaceutical and NKGen Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0	3	3	1	2.71
NKGen Biotech	0	0	0	0	0.00

Collegium Pharmaceutical presently has a consensus target price of $52.60, suggesting a potential upside of 87.39%. Given Collegium Pharmaceutical’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Collegium Pharmaceutical is more favorable than NKGen Biotech.

Summary

Collegium Pharmaceutical beats NKGen Biotech on 11 of the 13 factors compared between the two stocks.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.